Physician profile
Aaron J Mitchell
NPI 1275852188
$10,464.78
in general payments reported to CMS, 2019-2025
46 companies · $850 in 2025
The $850 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,185 · 2020: $1,150 · 2021: $2,155 · 2022: $2,384 · 2023: $1,707 · 2024: $1,034 · 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,591.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,397.08 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,385.83 | 2020-2025 | |
| Novo Nordisk INC | $1,242.97 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,195.22 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $562.25 | 2019-2023 | Mounjaro, Trulicity |
| Abbott Laboratories | $519.40 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $427.57 | 2019-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $410.72 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $405.15 | 2021 | |
| Janssen Pharmaceuticals, INC | $398.49 | 2019-2022 | |
| Amgen INC. | $331.87 | 2019-2025 | Repatha, Otezla, Otezla |
| Amarin Pharma, INC. | $281.70 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $191.71 | 2019-2023 | Vaxelis, Gardasil 9, Vaxneuvance |
| Sunovion Pharmaceuticals INC. | $163.85 | 2019-2022 | |
| Pfizer INC. | $142.03 | 2020-2025 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.